Updates of biological agents in the treatment of pediatric lupus nephritis / 中华实用儿科临床杂志

ABSTRACT

Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple systems and organs.Lupus nephritis (LN) is the most common and serious complication of SLE, which is an important cause of end-stage renal disease and death in children.With the in-depth exploration of the immune pathogenesis of SLE, the greatly accelerated development of biological agents significantly improve the prognosis of pediatric LN.This study aims to review the current situation of biological agents in the treatment of pediatric LN, which provides references for optimizing the clinical therapeutic strategies of pediatric LN.